Kantum's mission is to establish a new therapeutic paradigm
for AKI prevention and treatment.
DEDICATED TO THE PREVENTION AND TREATMENT OF ACUTE KIDNEY INJURY
Kantum Pharma founder to present preclinical data demonstrating beneficial effects of P2Y14 antagonist in Acute Kidney Injury at the American Society of Nephrology Annual Meeting.
Title: The P2Y14 Receptor: Linking the Intercalated Cell to Immune Defense
Presenter: Sylvie Breton, PhD, Professor of Medicine at Harvard Medical School
Time: Thursday November 7, at 3:30pm
Location: 146 C, Walter E. Washington Convention Center